SCHEMBL20157358

SCHEMBL20157358

COc1ccc(CNc2cc(Br)c(C(=O)O)cc2F)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.60
GAA P10253 3/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
APLNR P35414 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
LCK P06239 1/20 0.44
FYN P06241 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ASPH Q12797 1/20 0.43
KDM8 Q8N371 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20157655 0.87 MAPT (0.55) KDM4CGAAMAPTALDH1A1TDP1
SCHEMBL20157652 0.86 KDM4C (0.48) KDM4CGAAMAPTALDH1A1TDP1
SCHEMBL21351883 0.86 KDM4C (0.51) KDM4CGAAMAPTALDH1A1TDP1
SCHEMBL20157981 0.85 POLB (0.50) KDM4CGAAMAPTALDH1A1TDP1
SCHEMBL14994042 0.83 KDM4E (0.50) KDM4CGAAALDH1A1L3MBTL1KDM4E
SCHEMBL21555619 0.83 KDM4C (0.47) KDM4CGAAMAPTALDH1A1TDP1
SCHEMBL20157455 0.83 APLNR (0.49) KDM4CGAAMAPTALDH1A1TDP1
SCHEMBL21362495 0.82 APLNR (0.51) KDM4CGAAMAPTALDH1A1TDP1
SCHEMBL20157650 0.82 APLNR (0.51) KDM4CGAAMAPTALDH1A1TDP1
SCHEMBL25238776 0.80 KDM4C (0.54) KDM4CGAAMAPTALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. (CN) 2019-09-19 US disclosed
EP-3539960-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Luoxin Pharmaceutical (Shanghai) Co., Ltd. (CN) 2019-09-18 EP disclosed
WO-2018086605-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 山东罗欣药业集团股份有限公司 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190284192-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF MYC, BRD1, BRD3 KDM4C 1978/4885GAA 4852/4885MAPT 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.